Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced inducement equity grants on Jan 29, 2026, awarding non-qualified stock options for an aggregate of 81,100 shares to newly hired employees under its 2024 Inducement Plan.

The options’ exercise price equals the closing market price on the grant date. Vesting: 25% at the first anniversary, then monthly over three additional years, subject to continued employment.

Key Figures

Inducement options: 81,100 shares Q3 2025 net loss: $31.5 million Q3 2025 revenue: $0.7 million +5 more

8 metrics

Inducement options 81,100 shares Non-qualified stock options granted to new hires on Jan 29, 2026

Q3 2025 net loss $31.5 million Net loss for quarter ended Sep 30, 2025

Q3 2025 revenue $0.7 million Revenue from customers in Q3 2025

Q3 2025 R&D expense $23.9 million Research and development expenses for Q3 2025

Q3 2025 G&A expense $5.2 million General and administrative costs for Q3 2025

Warrant liability $13.4 million Fair value of 2023 common warrants as of Sep 30, 2025

PIPE gross proceeds $105.0 million February 2025 PIPE financing gross proceeds

Cash & investments $99.1 million Cash, cash equivalents and short-term investments as of Sep 30, 2025

Market Reality Check

Price: $8.07 Vol: Volume 49,442 vs 20-day a...

low vol

$8.07 Last Close

Volume Volume 49,442 vs 20-day average 81,497 (relative volume 0.61). low

Technical Price 8.12 is trading slightly below the 200-day MA at 8.37.

Peers on Argus

Peers show mixed moves (e.g., BYSI +0.65%, CVM -6.23%, IGMS -2.31%), and no peer...

Peers show mixed moves (e.g., BYSI +0.65%, CVM -6.23%, IGMS -2.31%), and no peers are in the momentum scanner, suggesting this hiring-related equity update is stock-specific rather than part of a sector-wide move.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Clinical trial update	Positive	-0.1%	Provided Phase 2 B‑SUPREME enrollment status and interim-analysis timing for HBV study.
Jan 13	Leadership appointment	Positive	+6.1%	Hired new EVP & Chief Commercial Officer to build global commercial capabilities.
Dec 12	Inducement grants	Neutral	+15.5%	Granted 14,100 stock options to new hires under 2024 Inducement Plan.
Dec 11	Data presentation	Positive	+1.6%	Presented positive Phase 1 HBV and obesity combination-therapy data at HEP‑DART 2025.
Nov 14	Inducement grants	Neutral	+9.7%	Announced 23,600 non-qualified stock options for new employees under inducement plan.

Pattern Detected

Recent news often aligned with share-price moves: leadership and scientific data updates saw positive reactions, while one clinical progress update prompted a slight divergence. Routine inducement grants have not shown a consistently negative reaction historically.

Recent Company History

Over the last several months, Aligos has combined clinical progress, leadership changes, and recurring inducement grants. A Phase 2 B‑SUPREME study update on Jan 21, 2026 produced a small negative reaction despite operational progress. Leadership was expanded with a new CCO on Jan 13, 2026, which coincided with a 6.08% move higher. Positive data at HEP‑DART 2025 and prior inducement grants in Nov and Dec 2025 also saw positive price reactions, framing today’s new-hire option grants as part of an ongoing hiring and development cycle.

Market Pulse Summary

This announcement details inducement stock option grants totaling 81,100 shares to new employees und...

Analysis

This announcement details inducement stock option grants totaling 81,100 shares to new employees under the 2024 Inducement Plan, consistent with prior hiring-related awards. It adds to a backdrop of ongoing clinical development and prior leadership strengthening. Investors tracking Aligos may focus on how these hires support key programs, the company’s reported Q3 2025 net loss of $31.5 million, and upcoming clinical milestones when assessing overall risk and progress.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), exercise price

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 81,100 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"have an exercise price per share equal to the closing price of Aligos’ common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on January 29, 2026 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

What did Aligos Therapeutics (ALGS) announce about inducement grants on January 29, 2026?

Aligos granted non-qualified stock options totaling 81,100 shares as inducement awards to new hires. According to the company, the grants were made under its 2024 Inducement Plan and priced at the closing market price on the grant date.

How do the ALGS inducement grants vest and when do they begin vesting?

The inducement options vest over a four-year schedule with 25% vesting at year one. According to the company, the remainder vests in equal monthly installments thereafter, contingent on continued employment through each vesting date.

What exercise price was set for the ALGS inducement stock options granted January 29, 2026?

The exercise price equals the closing price of Aligos common stock on the grant date. According to the company, each option’s strike was set at that closing market price on Jan 29, 2026.

Under which plan were the ALGS inducement grants issued and who is eligible?

The awards were issued under Aligos’ 2024 Inducement Plan, reserved for new hires. According to the company, the Plan is used exclusively to grant equity to individuals not previously employed by Aligos.

Will the ALGS inducement grants dilute existing shareholders and how material is the impact?

The company disclosed the aggregate option amount is 81,100 shares but did not quantify dilution percentage. According to the company, the grants were made as inducements; dilution impact depends on total shares outstanding.